Breaking News Instant updates and real-time market news.

WAGE

WageWorks

$51.65

0.91 (1.79%)

, HQY

HealthEquity

$62.16

-2.5 (-3.87%)

08:58
06/27/19
06/27
08:58
06/27/19
08:58

Fly Intel: Pre-market Movers

UP AFTER EARNINGS: Walgreens Boots Alliance (WBA), up 5%... KB Home (KBH), up 7%. ALSO HIGHER: OFG Bancorp (OFG), up 17% after the signing of a definitive agreement for OFG's subsidiary, Oriental Bank, to acquire Scotiabank's Puerto Rico operation for $550M in cash and Scotiabank's US Virgin Island branch operation for a $10M deposit premium... Novavax (NVAX), up 10% after announcing it will utilize the accelerated approval pathway for licensure for NanoFlu, its nanoparticle seasonal influenza vaccine candidate. DOWN AFTER EARNINGS: Conagra Brands (CAG), down 7%...McCormick (MKC), down 3%... Patterson Companies (PDCO), down 4%... Pier 1 Imports (PIR), down 18%... Rite Aid (RAD), down 3%. ALSO LOWER: WageWorks (WAGE), down 2% after entering into a definitive agreement under which HealthEquity (HQY) will acquire all of the issued and outstanding shares of common stock of the company for $51.35 per share in cash, representing a total enterprise value of approximately $2B. HealthEquity shares are up 7% following the deal announcement.

WAGE

WageWorks

$51.65

0.91 (1.79%)

HQY

HealthEquity

$62.16

-2.5 (-3.87%)

WBA

Walgreens Boots Alliance

$52.40

-0.59 (-1.11%)

KBH

KB Home

$23.58

-0.24 (-1.01%)

OFG

OFG Bancorp

$20.68

0.305 (1.50%)

NVAX

Novavax

$5.52

-0.08 (-1.43%)

CAG

Conagra Brands

$28.94

0.035 (0.12%)

MKC

McCormick

$150.58

-2.545 (-1.66%)

PDCO

Patterson Companies

$24.90

0.7 (2.89%)

PIR

Pier 1 Imports

$8.80

0.14 (1.62%)

RAD

Rite Aid

$7.11

0.26 (3.80%)

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 17

    Jul

WAGE WageWorks
$51.65

0.91 (1.79%)

06/05/19
JMPS
06/05/19
NO CHANGE
JMPS
Outperform
JMP says HealthEquity offer for WageWorks likely won't be last bid if rejected
JMP Securities analyst David Scharf said his "reading between the lines" of comments made by HealthEquity (HQY) management on the company's Q1 earnings call leads him to believe the company needs to offer a full range of products in order to maintain long-term competitiveness and scale. He interpreted CEO Jon Kessler's statement that "whether it's through the proposed transaction or other means, we intend to increase our sort of shelf space...and that's what we're going to do one way or the other" as saying that its only strategic choice is to either acquire WageWorks (WAGE) or build out the same capabilities. Given this view of the comments, Scharf believes if WageWorks' board rejects the current offer it "will not be the last" bid made by HealthEquity, the analyst tells investors in a research note.
05/10/19
SBSH
05/10/19
NO CHANGE
SBSH
Citi opens 'Positive Catalyst Watch' on HealthEquity ahead of WageWorks news
Citi analyst Stephanie Demko opened a "Positive Catalyst Watch" on shares of HealthEquity (HQY) saying she sees upside on any news from its WageWorks (WAGE) bid. A confirmed deal would allow HealthEquity to the outline synergy potential and full rationale of the acquisition, while no deal would see a recovery in HealthEquity shares, Demko tells investors in a research note. She likes the deal, noting it would expands HealthEquity's ability to sell to the small/medium employer channel and has the potential to unlock "significant" synergies. Demko keeps a Buy rating on HealthEquity.
05/07/19
WELS
05/07/19
DOWNGRADE
Target $50
WELS
Market Perform
Wells Fargo downgrades WageWorks amid review of HealthEquity bid
Wells Fargo analyst Jamie Stockton downgraded WageWorks (WAGE) to Market Perform from Outperform while raising his price target for the shares to $50 from $45. The stock is now 1% below the $50.50 all-cash offer that HealthEquity (HQY) announced on April 30 and WageWorks indicated it was evaluating, Stockton tells investors in a research note. The analyst believes HealthEquity could be willing to go higher but also finds it possible that the company believes WageWorks' growth prospects are not compelling enough to pay a higher amount. Further, WageWorks could decide to continue to pursue a turnaround, says Stockton, who sees the shares trading down to $43 if the company walks away from the deal. The analyst prefers to move to the sidelines at this point.
05/07/19
WELS
05/07/19
DOWNGRADE
WELS
Market Perform
WageWorks downgraded to Market Perform from Outperform at Wells Fargo
HQY HealthEquity
$62.16

-2.5 (-3.87%)

06/05/19
JPMS
06/05/19
NO CHANGE
Target $80
JPMS
Overweight
HealthEquity price target lowered to $80 from $91 at JPMorgan
JPMorgan analyst Anne Samuel lowered her price target for HealthEquity to $80 from $91 but maintains an Overweight rating on the name following the company's Q1 results. HealthEquity "continues to deliver," driving sales growth in excess of the market, Samuel tells investors in a research note. While the 2020 model is "somewhat constrained" by investments in future growth, the company is taking the right steps for long term share capture, says the analyst, who sees its 2021 EBITDA growth returning to ~30%.
06/05/19
BRRR
06/05/19
NO CHANGE
BRRR
Barrington reiterates Outperform on HealthEquity after Q1 beat
Barrington analyst Alexander Paris, Jr. reiterated an Outperform rating and $100 price target on HealthEquity after the company reported Q1 earnings results that beat consensus expectations, along with faised FY20 guidance. The analyst believes a "premium is warranted" for HealthEquity given its "current and prospective growth profile, its leading position within the market, the recurring nature and visibility of its revenue, the leverage inherent in the model and its high free cash flow conversion."
WBA Walgreens Boots Alliance
$52.40

-0.59 (-1.11%)

04/25/19
DESJ
04/25/19
INITIATION
DESJ
Buy
Desjardins initiates HEXO Corp, Canopy Growth, Aurora Cannabis with a Buy
Desjardins analyst John Chu initiated HEXO Corp (HEXO), Canopy Growth (CGC), and Aurora Cannabis (ACB) with a Buy rating and respective price targets of C$14, C$74, and C$16.50 as part of a broad research note, saying the "hype" around legalization of adult-use cannabis in Canada remains strong in spite of "underwhelming" early months of sales. The analyst attributes the challenges to ramp-up, logistical and distribution issues, but expects investors to consider the opportunity as a "global" one. Chu believes that "major" consumer packaged goods companies like Constellation (STZ), InBev (BUD), and Altria (MO), as well as retailers like Walgreens (WBA), CVS (CVS), and Rite Aid (RAD) should "help push cannabis and hemp into the mainstream."
04/18/19
04/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Morgan Stanley (MS) downgraded to Neutral from Buy at Citi with analyst Keith Horowitz saying Morgan Stanley reported "strong" Q1 results but the shares are fairly valued. 2. Snap (SNAP) downgraded to Negative from Mixed at Vertical Group and to Neutral from Outperform at Wedbush. 3. Rite Aid (RAD) downgraded with a Sell from Neutral at Guggenheim while Walgreens Boots Alliance (WBA) was downgraded with a Neutral from Buy. 4. CF Industries (CF) downgraded to Underperform from Buy at BofA/Merrill with analyst Steve Byrne saying he has spoken with 10 key channel contacts in the Cornbelt and several commented that never in their 30-plus year careers have they seen fertilizer applications this far behind, mainly due to the weather. 5. FMC Corporation (FMC) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the "uncertainty of Rynaxypyr and Cyazypyr patent expiration" as well as the reduced multiple from the recent lithium separation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/19
BARD
04/25/19
NO CHANGE
Target $336
BARD
Outperform
Smile Direct, CVS news 'good' for Align Technology, says Baird
Smile Direct Club announced an expanded agreement with CVS (CVS) and an agreement with Aetna Dental, which Baird analyst Jeff Johnson could likely drive additional clear aligner awareness, something that should be good for the industry, and, specifically Align Technology (ALGN), where early efforts with Walgreens (WBA) "seem to be developing" and where traction remains strong through DSOs. The analyst maintains an Outperform rating and $336 price target on Align Technology shares.
05/14/19
RAJA
05/14/19
NO CHANGE
RAJA
Walgreens could target Amerisource, LabCorp if it seeks M&A, says Raymond James
Raymond James analyst John Ransom said he thinks that "the temptation" for Walgreens (WBA) to do "something" in terms of M&A will grow over time and the "something" it may consider could include either acquiring AmerisourceBergen (ABC) or LabCorp (LH). His analysis points to LabCorp being a less complicated, "but much less accretive," deal, said Ransom. Given Walgreens' existing ownership of about a 26% stake in AmerisourceBergen, he estimates 16% accretion from buying the company for $95 per share in cash if he assumes $500M of synergies and $2B of opioid fines financed with debt, the analyst tells investors. Though such a deal would make financial sense, he does not think investors would "be overly excited about the strategic upside," Ransom tells investors. While he argues that LabCorp "offers more strategic upside," such a hypothetical deal also has less financial benefit, according to Ransom.
KBH KB Home
$23.58

-0.24 (-1.01%)

06/27/19
06/27/19
UPGRADE
Target $30

Overweight
KB Home upgraded to Overweight on earnings momentum, seasonal lift at KeyBanc
As previously reported, KeyBanc analyst Kenneth Zener upgraded KB Home to Overweight from Sector Weight, with a $30 price target. The analyst believes the company's Q2 order momentum warrants higher growth expectations. His seasonal quant model dictates his demand forecast, and coupled with KB Home's rising community count, delivers a much improved second half of 2019 and 2020 outlook, despite recent market news suggesting otherwise, he contends.
06/27/19
BUCK
06/27/19
UPGRADE
Target $30
BUCK
Buy
KB Home upgraded to Buy on strong community growth execution at Buckingham
As previously reported, Buckingham analyst Megan McGrath upgraded KB Home to Buy from Neutral and raised her price target on the shares to $30 from $27 following the company's strong Q2 results, citing her view that gross margins should see tailwinds from better geographic mix, firming prices and improving volume. Order growth of 15% came in well above her 4% growth estimate and she thinks continued community count growth should boost order growth in the second half of the year, McGrath noted.
06/27/19
BUCK
06/27/19
UPGRADE
BUCK
Buy
KB Home upgraded to Buy from Neutral at Buckingham
06/27/19
KEYB
06/27/19
UPGRADE
KEYB
Overweight
KB Home upgraded to Overweight from Sector Weight at KeyBanc
OFG OFG Bancorp
$20.68

0.305 (1.50%)

07/16/18
PIPR
07/16/18
UPGRADE
Target $17
PIPR
Overweight
OFG Bancorp upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Brett Rabatin upgraded OFG Bancorp(OFG) to Overweight and raised his price target for the shares to $17 from $15.50. The analyst has increased confidence on the bank's forward net interest margin and a move higher in its profitability over the next year. He believes the upcoming quarterly results will serve as catalysts for Puerto Rican banks Popular (BPOP), First BanCorp (FBP) and OFG.
NVAX Novavax
$5.52

-0.08 (-1.43%)

05/06/19
SBSH
05/06/19
NO CHANGE
Target $0.95
SBSH
Buy
Citi recommends buying Novavax ahead of regulatory update
Citi analyst Joel Beatty recommends buying Novavax because he sees a "favorable likelihood" that a regulatory update in the next month or so will reveal that the company can pursue the accelerated approval pathway for its flu vaccine. This would allow for Phase 3 results around January 2020, Beatty tells investors in a research note. The analyst sees ~25% upside / ~50% downside on whether accelerated approval is granted. He lowered his price target for Novavax shares to 95c from 95c from $1.25 and keeps a Buy rating on the shares.
03/19/19
HCWC
03/19/19
NO CHANGE
Target $2
HCWC
Buy
H.C. Wainwright sees pathway for Novavax approval, keeps $2 price target
Following the company's Q4 results and business update, H.C. Wainwright analyst Vernon Bernardino continues to believe a "strong investment thesis remains" for buying Novavax shares. The Prepare trial showed ResVax was safe, and importantly, resulted in clinically meaningful outcomes, Bernardino tells investors in a research note. While the stock remains down 76% from its closing price of $2.13 prior to the Prepare results, prospects for discussions with the FDA and European Medicines Agency, which are expected in the next 90 days, are positive, contends the analyst. He believe ResVax's pathway to approval is "under-appreciated" and would be a buyer of the stock. Bernardino keeps a Buy rating on Novavax with a $2.00 price target. The stock in midday trading is down fractionally at 52c.
03/19/19
SBSH
03/19/19
NO CHANGE
Target $1.25
SBSH
Buy
Citi cuts Novavax target to $1.25, sees three reasons to keep Buy
Citi analyst Joel Beatty lowered his price target for Novavax to $1.25 from $3.50 but maintains a Buy rating on the shares. While the recent failure of the Phase 3 respiratory syncytial virus vaccine trial was a "major setback" for the company, three potential upside opportunities collectively make the stock a Buy, Beatty tells investors in a research note. These include an accelerated approval pathway being confirmed by the FDA for NanoFlu, a scenario the analyst believes is "slightly more likely than not," a ResVax partnership is announced, and/or ResVax receiving approval in Europe.
05/13/19
OPCO
05/13/19
NO CHANGE
Target $25
OPCO
Outperform
Novavax price target raised to $25 from $1.25 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter raised his price target for Novavax to $25 from $1.25 to reflect the company's 1-for-20 stock split, effective May 10. The analyst reiterates an Outperform rating on the shares.
CAG Conagra Brands
$28.94

0.035 (0.12%)

06/11/19
EVER
06/11/19
INITIATION
Target $36
EVER
Outperform
Conagra Brands initiated with an Outperform at Evercore ISI
Evercore ISI analyst David Palmer started Conagra Brands with an Outperform rating and $36 price target.
04/11/19
JPMS
04/11/19
NO CHANGE
Target $34
JPMS
Overweight
JPMorgan sees 'much more upside' in Conagra, boosts target to $34
JPMorgan analyst Ken Goldman raised his price target for Conagra Brands to $34 from $30 saying he sees "much more upside" in the shares. The company's longer-term sales guidance seems conservative and beatable, Goldman tells investors in a research note. He also believes management is addressing a number of investor concerns, including the sustainability of the frozen category's strength, the reasons for reductions in A&P spending, and the plan to turn around Pinnacle. Goldman reiterates an Overweight rating on Conagra Brands.
05/20/19
MSCO
05/20/19
INITIATION
Target $31
MSCO
Equal Weight
Conagra Brands resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Pamela Kaufman resumed coverage of Conagra Brands with an Equal Weight rating and $31 price target. While she believes the company is well-positioned for revenue growth ahead of Packaged Food peers, she still sees risk with the turnaround of Pinnacle Foods and thinks the risk-reward appears balanced given recently rising expectations.
05/14/19
RHCO
05/14/19
INITIATION
Target $35
RHCO
Buy
Conagra Brands initiated with a Buy at SunTrust
SunTrust analyst William Chappell initiated Conagra Brands with a Buy rating and a price target of $35, saying the arrival of new management and its efforts to implement a "scalable, repeatable process" across the organization has led to growth in all of its business units. The analyst also sees signs of stabilization for packaged foods companies generally after a "challenging" few years amid a shift toward more favorable pricing and increased demographic tailwinds for frozen foods as more Millenials have children.
MKC McCormick
$150.58

-2.545 (-1.66%)

01/25/19
FBCO
01/25/19
NO CHANGE
Target $130
FBCO
Neutral
McCormick price target cut to $130 from $150 at Credit Suisse
Credit Suisse analyst Robert Moskow backed a Neutral rating on McCormick and cut his price target to $130 after the company's quarterly results, with EPS and operating profit that missed estimates. In a research note to investors, Moskow lowered his FY19 estimate to $5.21 from $5.45 and established a FY20 estimate of $5.73, but says he believes that the risk/reward is less balanced than in the past.
01/25/19
CEDG
01/25/19
UPGRADE
CEDG
Overweight
McCormick upgraded to Overweight from Equal Weight at Consumer Edge
01/25/19
01/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Flir Systems (FLIR) upgraded to Outperform from Neutral at Baird with analyst Peter Arment saying defense contract wins that are providing good visibility and current valuation, which provides a good risk/reward. 2. McCormick (MKC) upgraded to Hold from Sell at Deutsche Bank and to Overweight from Equal Weight at Consumer Edge. 3. Rockwell Automation (ROK) upgraded to Buy from Reduce at HSBC with analyst Michael Hagmann saying he views the correction in shares as "overdone" and said Rockwell offers robust secular automation fundamentals, strong cash flow generation, and best-in-class ROIC, with potential for end market improvement in FY19. 4. Triumph Group (TGI) upgraded to Outperform from Market Perform at Cowen with analyst Cai von Rumohr citing its Global 7500 program as it will reduce the company's risk, bolster 2020 free cash flow, and shift its mix to profitable sectors. 5. Carnival (CCL) upgraded to Outperform from Neutral at Macquarie with analyst Paul Golding citing valuation and favorable exposure to oil prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/13/19
05/13/19
NO CHANGE

Off Wall Street initiates short recommendation on McCormick
PDCO Patterson Companies
$24.90

0.7 (2.89%)

04/17/19
GUGG
04/17/19
INITIATION
GUGG
Neutral
Patterson Companies initiated with a Neutral at Guggenheim
Guggenheim analyst Glen Santangelo initiated Patterson Companies with a Neutral rating and a price target of $23. The analyst noted that "consensus expectations are low and valuation is somewhat compelling," but suggested caution due to the fairly new management team that is continuing to deal with "ongoing transitional issues and a difficult competitive landscape."
04/17/19
GUGG
04/17/19
INITIATION
Target $23
GUGG
Neutral
Patterson Companies initiated with a Neutral at Guggenheim
Guggenheim initiated Patterson Companies with a Neutral rating and $23 price target.
01/17/19
UBSW
01/17/19
INITIATION
Target $23
UBSW
Neutral
Patterson Companies initiated with a Neutral at UBS
UBS analyst Kevin Caliendo started Patterson Companies with a Neutral rating and $23 price target.
05/30/19
WOLF
05/30/19
INITIATION
Target $19
WOLF
Underperform
Patterson Companies initiated with an Underperform at Wolfe Research
Wolfe Research started Patterson Companies with an Underperform rating and $19 price target.
PIR Pier 1 Imports
$8.80

0.14 (1.62%)

01/08/19
GDHS
01/08/19
UPGRADE
GDHS
Hold
Pier 1 Imports upgraded to Hold from Underperform at Gordon Haskett
04/24/19
MSCO
04/24/19
NO CHANGE
Target $30
MSCO
Overweight
At Home could double market share, triple sales by 2028, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said he believes At Home Group (HOME) can drive meaningful share gains with its superior value proposition of the lowest prices, a wide assortment and high levels of in-stock inventory. Over the next ten years, he estimates At Home could double its market share and triple its revenue, highlighting Pier 1 Imports (PIR) as one of "many" potential share donor, stating that his analysis suggests At Home could capture greater than $110M in sales from Pier 1 over the next ten years. Gutman keeps an Overweight rating and $30 price target on At Home shares.
03/21/19
GDHS
03/21/19
DOWNGRADE
GDHS
Underperform
Pier 1 Imports downgraded to Underperform at Gordon Haskett
03/21/19
GDHS
03/21/19
NO CHANGE
GDHS
Gordon Haskett shakes up retailer rankings with six upgrades, three downgrades
Gordon Haskett analysts Chuck Grom, John Park and Andrew Minora have recalibrated their ratings in broadline and hardline retail with the Q4 earnings season nearly complete, stating that holiday results were mixed with clear winners and losers and that year-to-date sales have been "extremely choppy." The firm's latest macro/consumer survey results suggest that some optimism has resurfaced and they see a scenario where there is a release of significant pent-up demand for the retail group. Within the context of a portfolio approach to the space, the analysts upgraded Target (TGT), Tractor Supply (TSCO), Dollar Tree (DLTR), BJ's Wholesale (BJ) to Buy from Accumulate, upgraded Wayfair (W) and Floor & Decor (FND) to Accumulate from Hold, and downgrade Nordstrom (JWN) and Sprouts Farmers Market (SFM) to Reduce from Hold. The analysts also downgraded Pier 1 Imports (PIR) to Underperform from Hold.
RAD Rite Aid
$7.11

0.26 (3.80%)

04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim
Guggenheim analyst Glen Santangelo assumed coverage of Rite Aid and downgraded the shares to Sell from the firm's Neutral rating under analyst John Heinbockel. Santangelo also lowered the price target fro Rite Aid to 35c per share, down from 45c per share. The analyst believes Rite Aid's "significant debt burden" and "high leverage will continue to limit Rite Aid's ability to work through its structural and competitive issues."
04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.